Hematology

Non-Hodgkin Lymphoma

Questions discussed in this category

Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?

2 Answers available

How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?

2 Answers available

What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?

3 Answers available

How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?

Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?

4 Answers available

Are you including Bortezomib as standard of care in the upfront treatment of T lymphoblastic-lymphoma?

1 Answer available

For pediatric patients with localized diffuse large B-cell lymphoma being treated per COG ANHL 1131 in group B, do you feel it is necessary to complete all lumbar punctures with IT therapy?

2 Answers available

What are your practical considerations for incorporating bispecific antibody therapy into treatment of relapsed DLBCL?

2 Answers available

How are you deciding between available third line therapies for post-transplant relapsed DLBCL?

In a patient who relapsed following 2nd line transplant, how do you select CAR-T vs bispecifics vs non-T-cell-mediated therapies as outlined in NCCN? ...

2 Answers available

How should community oncologists practically counsel patients with aggressive lymphomas on the potential treatment course as they move into 2L/3L therapies?

Do you speak to different expectations re: ability to achieve PR/CR and/or how this will impact ability to get to later therapies for a patient with p...

2 Answers available

Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?

Is the data sufficient to change your practice?

2 Answers available

Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?

Does cumulative exposure to BTKi increase potential risk of cardiac toxicity?

2 Answers available

What subsequent therapies did patients receive after progressing on pirtobrutinib in the mantle cell BRUIN trial population?

Should pirtobrutinib be viewed as a bridge to CAR-T or transplant or a destination therapy?

2 Answers available

Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?

How do you predict which patients may be in a high risk group and less likely to benefit from a second BTKi?